In addition, we studied the psychological effects of receiving an abnormal test result. Patients were sent a validated psychological questionnaire to measure anxiety and self-reported health on entry to the study and again at the 2-year follow-up point. A qualitative study was conducted after 2 years to explore perceptions of the effects of participating in the BALLETS study, and of abnormal test results, on behaviours and attitudes toward health. Clinicians' motivations for ordering LFTs were explored by means of a semistructured interview. We created a decision-analytic model to evaluate strategies that might be pursued in the face of an abnormal LFT result and to identify the most efficient option. Lastly, we conducted a preliminary study of a liver fibrosis score that might identify cases of 'fatty liver' at greatest risk of progression.
Results
1. Fewer than 5% of people with abnormal LFT results had a specific disease affecting the liver and there was a serious liver disease requiring immediate therapy in 1.3% of cases (all 13 cases of viral hepatitis and four cases of homozygous haemochromatosis). 2. The majority of serious or potentially serious diseases can be detected by just two analytes alanine aminotransferase (ALT) and alkaline phosphatase (ALP) from the LFT panel of eight analytes. The ALT enzyme is sensitive for hepatocellular disease, whereas ALP is sensitive for both hepatobiliary diseases and systemic diseases (such as metastatic cancer) affecting the liver. 3. Aspartate aminotransferase (AST) adds little to ALT and is considerably less sensitive (although it is slightly more specific). 4. The gamma-glutamyltransferase (GGT) enzyme was the most frequently abnormal analyte with a very high false-positive rate, but offered only a marginal increase in sensitivity in return. Unlike other analytes, the degree of abnormality is not indicative of the probability of disease. This is consistent with the poor discriminatory characteristics of this test in determining the presence, or absence, of pathology. GGT levels were sensitive, however, to alcohol intake. 5. Protein levels (albumin, globulin and total protein) are the least frequently abnormal analytes and they are typically only very 'mildly' abnormal. Albumin increases with age and comorbidity, but was not strongly related to any disease involving the liver. 6. Viral hepatitis was found in 1% of patients. Nine of the 13 patients with chronic viral hepatitis had more than one abnormal analyte and ALT was the most commonly abnormal analyte, followed closely by AST. The degree of ALT and AST abnormalities was, on average, considerably higher in patients with viral hepatitis than in the remaining patients. Country of origin (not ethnic group) was, by a considerable margin, the strongest predictor of viral hepatitis. 7. Guidelines recommend repeating LFTs in the event of an abnormal result, but 84% of tests remained abnormal on retesting after an average of 1 month, and even at 2 years 75% remained abnormal. Modelling confirmed the intuition that it is frequently more efficient, when confronted by an abnormal LFT, to proceed directly to a specific test rather than repeat the LFT with a view to specific testing only if it remains abnormal. 8. Nearly 4 in 10 patients had a 'fatty liver' on ultrasound, and an abnormal ALT level was the strongest laboratory predictor of this finding. Obesity was more strongly associated with 'fatty liver' than with alcohol use, but one-quarter of patients with 'fatty liver' were neither overweight nor excessive alcohol drinkers. 9. A small amount of weight loss over 2 years (1.3% reduction in body mass index) was associated with a reduced incidence of 'fatty liver'. There was a J-shaped relationship between alcohol intake and 'fatty liver' in men. 10. An abnormal LFT result generated anxiety and this anxiety was non-significantly greater if the liver was 'fatty.' However, anxiety dissipated over 2 years. Recall of an abnormal test result was hazy after 2 years and a tendency towards greater weight loss in patients with 'fatty liver' was not statistically significant.
NIHR Journals Library www.journalslibrary.nihr.ac.uk SCIENTIFIC SUMMARY: Birmingham and LamBeth Liver evaLuation testing strategies (BaLLets) iv 11. Doctors' motivations for performing LFTs are mixed, and the tests are often carried out to meet perceived patient need for a 'blood test' or as a defensive practice. There was evidence that they were often undertaken as a semiautomatic or 'tick-box' response. 12. Eight per cent of patients with non-alcoholic 'fatty liver' had a fibrosis score that has been shown to be associated with a progressive disease in hospital-based studies.
Conclusions
1. It is unusual for an abnormal LFT result to signify a serious treatable disease of which the doctor was previously unaware. 2. Liver function tests are often carried out for social and psychological, rather than clinical, reasons.
Given the high false-positive rate of LFTs and the fact that an abnormal result does not signal any particular disease, we recommend a more selective approach to this particular 'blood test'. 3. Aspartate aminotransferase is less sensitive than ALT for hepatocellular diseases, and GGT is very non-specific. There is a case for omitting these tests from the standard LFT panel and holding them in reserve for patients in whom alcohol abuse is suspected. 4. The standard advice to repeat an abnormal LFT does not gain support from the decision model and was one of the least efficient strategies with respect to diagnosis of viral hepatitis. 5. Country of origin is the strongest predictor of viral hepatitis among people with abnormal LFTs.
6. An abnormal ALT is strongly predictive of a 'fatty liver', as is obesity. If a person is obese and has a high ALT then an ultrasound diagnosis of 'fatty liver' is very probable. 7. There is no good evidence that single abnormal LFTs or ultrasound findings promote healthy behaviour.
Implications for practice
1. Liver function tests should be used sparingly in primary care. 2. The default LFT panel of five to eight analytes is obsolete. 3. When a chronic disease affecting the liver is suspected, a panel of two analytes (ALT and ALP) should be used, supplemented by bilirubin if an acute disease or poisoning is suspected. 4. When the clinician wishes to exclude a non-liver disease or simply reassure the patient, a selection should be made from a 'dropdown' menu of tests, and tests that provide a clear pointer to the next appropriate step should be favoured. 5. All patients who drink too much alcohol or who are obese should be given appropriate advice, irrespective of their LFT result. A single abnormal LFT does not promote healthy behaviour and use of serial LFTs to promote behaviour change is an unproven therapy that might do more harm than good.
Implications for research 1. A pilot study of a 'customised' approach to test ordering should be considered. The clinical value of different tests when patients have vague symptoms, such as tiredness or upper abdominal pain, should be evaluated. Likewise, the need to carry out more blood tests when patients are on treatment for chronic disease, such as hypertension, is unclear. There is a mismatch between the frequency with which blood tests are used to monitor chronic diseases and investigate symptoms, on the one hand, and scientific exploration of this subject, on the other. 2. The BALLETS cohort should be followed up over time to find out whether it is possible to identify the minority of patients with 'fatty liver' who are likely to progress to cirrhosis and to evaluate the fibrosis score in a primary-care setting.
